Phase I/II Study of hLL1 in Multiple Myeloma

A Phase I/II Study of Immunotherapy With hLL1 Administered Twice Weekly for 4 Consecutive Weeks in Patients With Multiple Myeloma

Sponsor(s)

Immunomedics

Principal Investigator(s)Jonathan L Kaufman, MD
Dates10/16/2007 - 10/31/2013